Universal Health Services raised its full-year exchange-market headwind estimate to $85 million from $75 million and lowered adjusted-admissions growth guidance at its Wells Fargo Healthcare Conference presentation on Tuesday, reflecting persistent payer and cost pressures even as the company posted modest second-quarter gains.
UHS (UHS) shares fell 1.74% to close at $172.72 on the day of the conference. The provider, which has a market capitalization of roughly $10 billion and trailing twelve-month revenue of $18.1 billion, raised expectations for the drag from marketplace dynamics after exchange enrollment declined more sharply than assumed.
Adjusted admissions rose 2.9% in the second quarter and 1.4% in the first half, the company said. Full-year adjusted admissions growth guidance was cut to 1.5%–2.5%, from the previous 2%–3% range. The acute-care midpoint slipped to 2% from 2.5%. On a decade-long basis, acute-care adjusted admissions have grown at a 2%–2.5% average, CFO Steve Filton said, adding that the revised midpoint remains within that historical range.
Surgical volumes fell 0.8% in Q2. Long-term acute care has averaged between 2% and 2.5% growth over the past ten years.
The company also lowered its full-year EBITDA as NCI midpoint guidance by roughly 3%, though UHS still expects roughly 3% year-over-year EBITDA growth. Filton cited unfavorable discrete items as the driver.
Exchange-market pressures accounted for much of the guide reduction. UHS now expects an $85 million unfavorable impact in 2026, with $35 million realized in the first half and $50 million projected for the second half, which the company treats as a run rate into 2027. The shift to bronze-tier exchange plans affects approximately 25% of its exchange membership, and federal estimates suggest about 4% of Medicaid enrollees could lose coverage because of work requirements. Total exchange enrollment is expected to decline 25%–30% due to lapsing subsidies, nearly wiping out anticipated commercial substitutions.
Malpractice costs also weighed on the outlook. Expense runs at about 1% of revenue, or $175 million–$200 million annually, growing at 10%–15% per year — faster than the 4%–5% inflation rate. Filton described the spending as averaging roughly 1% of revenue.
In behavioral health, adjusted patient days rose 1.5% in the first half of 2026, up from 0.9% growth in 2025, but the full-year target was trimmed to 1%–2% from 2%–3%. The Talkspace acquisition, completed in mid-August alongside a $1.1 billion bond issuance, will add about $250 million in annual outpatient behavioral revenue and provides access to a panel of 6,000 therapists. UHS expects the deal to be slightly accretive in its first twelve months, with the impact immaterial for the remainder of 2026.
On operations, UHS added 177 acute-care beds in Q2 across three facilities — a new tower at Lakewood Ranch in the Sarasota market, a sixth-floor build-out at Henderson Hospital in Las Vegas adding 35–40 beds, and a replacement facility in Riverside County, Southern California. The Cedar Hill campus near Washington, D.C., opened in April 2025; emergency-room activity is strong while elective procedures continue to ramp, with the site expected to reach break-even by the fourth quarter of 2026. The George Washington University Physician Group transitioned to UHS ownership in July 2026, bringing 350 specialists and ending subsidy payments the company previously made to the university.
At its San Antonio campus, Laurel Ridge is operating with a reduced census while seeking CMS recertification, with full operations targeted for early 2027. The company also continued its Thousand Branches initiative, building freestanding outpatient facilities to serve step-down patients needing intensive outpatient or partial hospitalization programs.
Wall Street analysts maintained a consensus rating between Hold and Buy, with a price-target range of $166 to $290.
